Literature DB >> 31395463

Taiwanese consensus recommendations for acute pancreatitis.

Wei-Chih Liao1, Tien-Chien Tu2, Kuei-Chuan Lee3, Jseng-Hwei Tseng4, Ming-Jen Chen5, Cheuk-Kay Sun6, Shang-Yu Wang7, Wei-Kuo Chang8, Pi-Yi Chang9, Ming-Shun Wu10, Tsung-Jung Lin11, Hsiang-Lin Lee12, Jiann-Hwa Chen13, Kuo-Ching Yuan14, Nai-Jen Liu15, Hsing-Chien Wu16, Po-Chin Liang17, Hsiu-Po Wang1, Tsann-Long Hwang18, Chia-Long Lee19.   

Abstract

The incidence of acute pancreatitis and related health care utilization are increasing. Acute pancreatitis may result in organ failure and various local complications with risks of morbidity and even mortality. Recent advances in research have provided novel insights into the assessment and management for acute pancreatitis. This consensus is developed by Taiwan Pancreas Society to provide an updated, evidence-based framework for managing acute pancreatitis.
Copyright © 2019 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute pancreatitis; Diagnosis; Management

Year:  2019        PMID: 31395463     DOI: 10.1016/j.jfma.2019.07.019

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  2 in total

Review 1.  Analgesia in the Initial Management of Acute Pancreatitis: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

Authors:  Navamayooran Thavanesan; Sophie White; Shiela Lee; Bathiya Ratnayake; Kofi W Oppong; Manu K Nayar; Linda Sharp; Asbjørn Mohr Drewes; Gabriele Capurso; Enrique De-Madaria; Ajith K Siriwardena; John A Windsor; Sanjay Pandanaboyana
Journal:  World J Surg       Date:  2022-01-07       Impact factor: 3.282

2.  Increased Risk of Pyogenic Liver Abscess after Endoscopic Sphincterotomy for Treatment of Choledocholithiasis.

Authors:  Cheng-Kun Wu; Chien-Ning Hsu; Wei-Ru Cho; Shih-Cheng Yang; An-Che Liu; Wei-Chen Tai; Chen-Hsiang Lee; Yao-Hsu Yang; Seng-Kee Chuah; Chih-Ming Liang
Journal:  Infect Drug Resist       Date:  2021-06-08       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.